| 4/24/2025 | CV | Insmed corrects conversion rate for 0.75% convertibles due 2028
|
| 4/24/2025 | CVLM | Insmed calls remaining $569.5 million of 0.75% convertibles due 2028
|
| 10/31/2024 | PV | Insmed adds $150 million senior secured tranche to BioPharma term loan
|
| 8/9/2024 | CVLM | Insmed only redeems $198,000 of 1.75% convertibles due 2025
|
| 6/27/2024 | CVLM | Insmed calls all $225 million 1.75% convertible notes due 2025
|
| 5/28/2024 | CV | Market Commentary: Microchip convertibles on tap; Alarm.com eyed; Alibaba dominates trading; Insmed active
|
| 8/29/2023 | CV | Market Commentary: Akamai convertible notes break par; NextEra, Insmed paper active; Coinbase gains
|
| 8/7/2023 | CV | Market Commentary: Convertible primary floodgates open; Hannon Armstrong, Fluor, Envista on deck
|
| 10/19/2022 | PV | Insmed signs $350 million senior secured term loan with BioPharma
|
| 10/7/2021 | CV | Market Commentary: Sea surges in active trade; Square, LendingTree add with shares; Golar maturity eyed
|
| 10/7/2021 | CV | Market Commentary: Morning Commentary: Novavax convertibles trade with higher shares; Insmed notes eyed
|
| 5/13/2021 | CV | Insmed greenshoe lifts 0.75% convertibles due 2028 to $575 million
|
| 5/12/2021 | CV | Market Commentary: Fluor on tap; ON Semiconductor convertibles contract; ‘No-Nos’ under pressure; Insmed up
|
| 5/11/2021 | CV | Market Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket amid market volatility
|
| 5/11/2021 | CV | Market Commentary: Morning Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket
|
| 5/11/2021 | CVLM | Insmed to redeem $225 million of its 1.75% convertibles due 2025
|
| 5/11/2021 | CV | New Issue: Insmed sells $500 million seven-year convertible notes to yield 0.75%, up 30%
|
| 5/10/2021 | CV | Market Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax, ON Semiconductor on deck
|
| 5/10/2021 | CV | Market Commentary: Morning Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax on deck
|
| 5/10/2021 | CV | Insmed talks $500 million seven-year convertible notes to yield 0.5%-1%, up 25%-30%
|
| 2/3/2020 | CV | Market Commentary: Integra convertibles on tap; Tesla ‘a beast’; Luckin Coffee volatile; Insmed expands
|
| 2/3/2020 | CV | Market Commentary: Morning Commentary: Luckin Coffee convertible rebounds slightly; Insmed jumps outright
|
| 1/28/2020 | CV | Market Commentary: Semiconductor names eyed in convertibles market amid earnings; Insmed notes expand
|
| 6/17/2019 | CV | Market Commentary: Morning Commentary: Secondary trading light; health care sector boosted by Array buyout
|
| 5/7/2019 | CV | Market Commentary: Tesla’s new convertible notes come in; Microchip active; Insmed trades down outright
|
| 1/7/2019 | CV | Market Commentary: Convertibles secondary tone improves; Ares Capital dominates trading; biotechs strong
|
| 1/7/2019 | CV | Market Commentary: Morning Commentary: Ares Capital continues to dominate trading; biotech tape strong
|
| 12/19/2018 | CV | Market Commentary: Benefitfocus on tap; Micron drops outright, expands dollar-neutral; Insmed contracts
|
| 10/3/2018 | CV | Market Commentary: Tilray on tap; Boingo convertibles expand on debut; Apollo Commercial trades flat
|
| 10/1/2018 | CV | Market Commentary: Boingo on tap; convertibles trading light; Tesla rebounds; Insmed, Infinera contract
|
| 10/1/2018 | CV | Market Commentary: Morning Commentary: Tesla stock surges, convertibles less active; Insmed drops outright
|
| 8/14/2018 | CV | Market Commentary: FTI Consulting on tap; Microchip has its volatility event; Booking active; Insmed down
|
| 8/3/2018 | CV | Market Commentary: Convertibles space sees quiet end to week; Greenlight ‘buttoned up’; Insmed volatile
|
| 7/11/2018 | CV | Market Commentary: Sempra’s convertible preferreds trade up; Palo Alto, Twitter in focus; biotech active
|
| 5/2/2018 | CV | Market Commentary: Five9, Teladoc on tap; JPMorgan/Voya notes, IAC convertibles active; Ironwood eyed
|
| 4/23/2018 | CV | Market Commentary: JPMorgan on tap; Clovis contraction continues; Insmed improves; Ctrip.com, NXP active
|
| 4/23/2018 | CV | Market Commentary: Morning Commentary: NXP Semiconductors active in early trading; Insmed convertible notes improve
|
| 4/17/2018 | CV | Market Commentary: South Jersey, Deutsche on tap; Clovis convertibles ‘well received’; oil still catching bids
|
| 4/12/2018 | CV | Market Commentary: Transocean convertibles in focus; primary quiet; biotech sector firm; Caesars active
|
| 4/2/2018 | CV | Market Commentary: ‘Soft tape’ in convertibles space; Chegg maintains strength; recent deals below par
|
| 3/26/2018 | CV | Market Commentary: Landmark convertible preferreds on tap; Blackstone Mortgage at par; Live Nation active
|
| 3/26/2018 | CV | Market Commentary: Morning Commentary: Blackstone up to par in small-volume trades; Insmed active
|
| 2/23/2018 | CV | Market Commentary: Okta’s convertibles expand on debut; Q2 trading activity tempers; Exact Sciences lower
|
| 2/2/2018 | CV | Market Commentary: Convertibles settle down; ‘rough tape’ for recent biotech deals; Lam Research tumbles
|
| 2/2/2018 | CV | Market Commentary: Morning Commentary: Convertibles market settles down; ‘rough tape’ for recent biotech deals
|
| 2/1/2018 | CV | Market Commentary: Western Digital holds strong; recent deals still ‘licking wounds’; Shutterfly soars
|
| 1/30/2018 | CV | Market Commentary: Alder ‘getting smoked’; Western Digital deal a landmark; new paper adding pressure
|
| 1/29/2018 | CV | Market Commentary: Western Digital to price $1 billion; Alder richens deal; convert market ‘trying to absorb’ new paper
|
| 1/29/2018 | CV | Market Commentary: Morning Commentary: Alder BioPharmaceuticals to sell convertibles; market off to slow start
|
| 1/26/2018 | CV | Insmed greenshoe exercised, lifts 1.75% convertibles to $450 million
|
| 1/25/2018 | CV | Market Commentary: Senseonics, Oil States on tap; First Majestic hits market; new paper active; Nutanix drops
|
| 1/25/2018 | CV | Market Commentary: Morning Commentary: Oil States to price; First Majestic hits market; new paper active
|
| 1/24/2018 | CV | Market Commentary: First Majestic to price; Oil States on tap; Insmed dominates; ‘borrow tight’ on Teekay
|
| 1/24/2018 | CV | Market Commentary: Morning Commentary: Insmed, Teekay price new convertible notes; ‘borrow tight’ on Teekay
|
| 1/24/2018 | CV | New Issue: Insmed prices upsized $400 million seven-year convertibles to yield 1.75%, up 35%
|
| 1/23/2018 | CV | Market Commentary: Teekay eyes deal; Insmed seen as cheap; new paper active; Priceline gains on new CFO
|
| 1/23/2018 | CV | Market Commentary: Morning Commentary: Convertibles primary market awaits Insmed deal, initially seen as cheap
|
| 1/22/2018 | CV | Market Commentary: Insmed eyes deal; secondary market ‘not moving’; Exact Sciences, optic companies lose footing
|
| 1/22/2018 | CV | Insmed talks $300 million seven-year convertibles to yield 1.75% to 2.25%, up 27.5% to 32.5%
|
| 8/11/2014 | PP | Insmed plans to conduct $80 million public offering of common stock
|
| 7/22/2013 | PP | Insmed taps greenshoe, lifts public stock offering to $71.76 million
|
| 7/17/2013 | PP | Insmed prices $62.4 million public offering of common stock at $10.40
|
| 7/15/2013 | PP | Insmed plans to price $60 million public offering of common stock
|
| 7/2/2012 | PP | Insmed secures $10 million of $20 million variable-rate loan financing
|
| 6/14/2012 | CVHYPF | Insmed files $75 million shelf for debt securities, stock, preferreds
|
| 3/1/2011 | CVLMPF | Insmed converts series B preferreds, plans reverse stock split
|
| 2/12/2009 | SS | Market Commentary: Dow dividend cut no relief for Rohm; Cisco, VMware deal not in the cards; PharmaNet buyout a low risk
|
| 5/4/2007 | PP | New Issue: Insmed to close $18.23 million direct placement of shares
|
| 5/4/2007 | PP | Market Commentary: Spectrum prices $32.08 million direct stock offering; Insmed plans $18.23 million stock sale
|
| 11/10/2006 | BT | Market Commentary: Tanox soars 45% on Genentech buy; Targeted Genetics adds 26%, Pozen higher; Insmed, Tercica better
|
| 11/3/2006 | BT | Insmed's cash position increases by $16.2 million, net loss reaches $12.4 million for Q3
|
| 10/18/2006 | BT | Insmed becomes commercial company with launch of Iplex
|
| 10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
| 7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
| 7/18/2006 | BT | Market Commentary: Tercica up 12%, Insmed rises 9%; Neurocrine closes weaker; Pharma Product up; New River deal emerges
|
| 7/7/2006 | BT | Market Commentary: LifeCell lower; CV Therapeutics loses 2%; Indevus up; Tercica off by 8%; Amarillo Biosciences off
|
| 7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
| 7/5/2006 | BT | Court rules Insmed infringes Tercica IGF-1 process patent
|
| 6/28/2006 | BT | Market Commentary: Replidyne debut shaky but closes in the green; Indevus rises in face of spot sale; Depomed loses 3%
|
| 6/27/2006 | BT | Insmed reports positive results from three studies of Iplex
|
| 6/27/2006 | BT | Market Commentary: Insmed drops 11%; Vasogen up slightly; Anadys falls more; DOV, Discovery Labs up; Genelabs gains
|
| 6/9/2006 | BT | Insmed creates special pricing system for Iplex launch
|
| 4/26/2006 | BT | Insmed preliminary data shows Iplex helps children grow
|
| 4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
| 3/22/2006 | BT | Insmed offering, cash allow continued operations through second-quarter 2007
|
| 3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
| 3/15/2006 | BT | Insmed greenshoe exercised, raising follow-on sale to $46 million
|
| 3/10/2006 | BT | New Issue: Insmed raises $40 million in follow-on of 20 million shares at $2 each, discounted from $2.19 close
|
| 3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
| 3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
| 3/6/2006 | BT | Insmed plans follow-on of 20 million shares via Lazard
|
| 3/6/2006 | BT | Market Commentary: Cubist players hedging bets with puts; Insmed follow-on emerges; Elan up; Titan zooms; LifeCell up
|
| 2/27/2006 | BT | Market Commentary: Novavax bags $20 million, up 12%; BioCryst, Generex, Gilead also take flight; Cerus deal emerges
|
| 2/3/2006 | BTCV | Insmed files $75 million shelf
|
| 12/13/2005 | BT | Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
|
| 12/12/2005 | BT | Insmed's Iplex approved by FDA for growth failure in children
|
| 8/17/2005 | BT | Market Commentary: Access in talks to dodge a forced bankruptcy; Exelixis trades down to follow-on level; Insmed seesaws
|
| 3/15/2005 | PP | New Issue: Insmed raises $35 million in private placement of convertibles
|
| 11/8/2004 | PP | New Issue: Insmed raises $8.7 million in private placement of stock, warrants
|
| 11/8/2004 | PP | Market Commentary: Private placement action moderate in mixed market; Medarex gets $50 million in licensing deal
|
